Patents by Inventor Liangjun Lu

Liangjun Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150119400
    Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Inventors: Iok C. Ng, Liangjun Lu, Tanya Dekhtyar, Thomas Reisch, Rakesh L. Tripathi, Ron Pithawalla, Christine A. Collins, Tami J. Pilot-Matias
  • Publication number: 20150119319
    Abstract: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Ming Yeung, Timothy Middleton, Liangjun Lu, Kevin Kurtz
  • Patent number: 8937041
    Abstract: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: January 20, 2015
    Assignee: AbbVie, Inc.
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Ming Yeung, Timothy Middleton, Liangjun Lu, Kevin Kurtz
  • Patent number: 8338605
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: December 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Todd W. Rockway, David A. Betebenner, Allan C. Krueger, Nobuhiko Iwasaki, Curt S. Cooper, David D. Anderson, Dale J. Kempf, Darold L. Madigan, Christopher E. Motter, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V. L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Patent number: 8236950
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 7, 2012
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, Clarence J. Maring, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Publication number: 20120172291
    Abstract: The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: December 29, 2011
    Publication date: July 5, 2012
    Inventors: Keith F. McDaniel, Hui-Ju Chen, Ming Yeung, Timothy Middleton, Liangjun Lu, Kevin Kurtz
  • Publication number: 20110160233
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Application
    Filed: December 19, 2007
    Publication date: June 30, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: David A. Betebenner, Clarence J. Maring, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie VL. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Patent number: 7915411
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: March 29, 2011
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, David A. DeGoey, Clarence J. Maring, Allan C. Krueger, Nobuhiko Iwasaki, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Pamela L. Donner, Brian E. Green, Dale J. Kempf, Dachun Liu, Keith F. McDaniel, Darold L. Madigan, Christopher E. Motter, John K. Pratt, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu, David J. Grampovnik
  • Patent number: 7910595
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: March 22, 2011
    Assignee: Abbott Laboratories
    Inventors: David A. Betebenner, David A. DeGoey, Clarence J. Maring, Allan C. Krueger, Nobuhiko Iwasaki, Todd W. Rockway, Curt S. Cooper, David D. Anderson, Pamela L. Donner, Brian E. Green, Dale J. Kempf, Dachun Liu, Keith F. McDaniel, Darold L. Madigan, Christopher E. Motter, John K. Pratt, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu, David J. Grampovnik
  • Publication number: 20100256139
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 7, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Todd W. Rockway, David A. Betebenner, Allan C. Krueger, Nobuhiko Iwasaki, Curt S. Cooper, David D. Anderson, Dale J. Kempf, Darold L. Madigan, Christopher E. Motter, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie V.L. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Patent number: 7763731
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: July 27, 2010
    Assignee: Abbott Laboratories
    Inventors: Todd W. Rockway, David A. Betebenner, Allan C. Krueger, Nobuhiko Iwasaki, Curt S. Cooper, David D. Anderson, Dale J. Kempf, Darold L. Madigan, Christopher E. Motter, Jason P. Shanley, Michael D. Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami J. Pilot-Matias, Sherie VL. Masse, Robert J. Carrick, Wenping He, Liangjun Lu
  • Publication number: 20070232645
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Application
    Filed: December 20, 2006
    Publication date: October 4, 2007
    Inventors: Todd Rockway, David Betebenner, Allan Krueger, Nobuhiko Iwasaki, Curt Cooper, David Anderson, Dale Kempf, Darold Madigan, Christopher Motter, Jason Shanley, Michael Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami Pilot-Matias, Sherie Masse, Robert Carrick, Wenping He, Liangjun Lu
  • Publication number: 20070232627
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Application
    Filed: December 20, 2006
    Publication date: October 4, 2007
    Inventors: David Betebenner, David DeGoey, Clarence Maring, Allan Krueger, Nobuhiko Iwasaki, Todd Rockway, Curt Cooper, David Anderson, Pamela Donner, Brian Green, Dale Kempf, Dachun Liu, Keith McDaniel, Darold Madigan, Christopher Motter, John Pratt, Jason Shanley, Michael Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami Pilot-Matias, Sherie Masse, Robert Carrick, Wenping He, Liangjun Lu, David Grampovnik
  • Publication number: 20070197558
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.
    Type: Application
    Filed: December 20, 2006
    Publication date: August 23, 2007
    Inventors: David Betebenner, David DeGoey, Clarence Maring, Allan Krueger, Nobuhiko Iwasaki, Todd Rockway, Curt Cooper, David Anderson, Pamela Donner, Brian Green, Dale Kempf, Dachun Liu, Keith McDaniel, Darold Madigan, Christopher Motter, John Pratt, Jason Shanley, Michael Tufano, Rolf Wagner, Rong Zhang, Akhteruzzaman Molla, Hongmei Mo, Tami Pilot-Matias, Sherie Masse, Robert Carrick, Wenping He, Liangjun Lu, David Grampovnik